Partnerships and co-selling for Series B companies: scaling without breaking for healthcare and life sciences in the DACH region

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the DACH region. In this market, DACH buyers reward rigour, documentation, and long-cycle trust — not urgency-led campaigns, so the way you install partnerships and co-selling has to be shaped to that reality from day one.

Series B is the stress test for partnerships and co-selling. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, sourced and influenced pipeline from partners, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the DACH region it is compounded by the fact that trust-building cycle length, not intent is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of partnerships and co-selling is signing MOUs no one operationalises, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on sourced and influenced pipeline from partners outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run partnerships and co-selling function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences in the DACH region: the healthcare teams that install this get past procurement instead of dying in it, and one properly-run DACH account survives leadership changes and compounds for years. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.